Theravance Biopharma TBPH
NASDAQ TBPH
$17.03 +0.00 (+0.00%)
At close: Sep 25, 2026 · 4:00 PM EDT

Theravance Biopharma (TBPH) EV to EBITDA (2026)

Updated

Theravance Biopharma's EV to EBITDA came in at 149.99 for Q1 2026.

Analysis

Theravance Biopharma (TBPH) EV to EBITDA (2026) Analysis & Trends

Over the trailing twelve months to Mar 31, 2026, Theravance Biopharma reported EV to EBITDA of -184.31.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Theravance Biopharma 883.70 Mn -543.66 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 149.99
API Access

Theravance Biopharma EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=TBPH&period=max&api_key=YOUR_API_KEY